1 / 24

Monitoring and inhibiting phase separation of amorphous solid dispersions

Pharmaceutica 2015 Dubai 16 th April 2015. Monitoring and inhibiting phase separation of amorphous solid dispersions. Dr Min Zhao Min.zhao@ucl.ac.uk Department of Pharmaceutics UCL School of Pharmacy, UK. 1. Content.

eharper
Download Presentation

Monitoring and inhibiting phase separation of amorphous solid dispersions

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Pharmaceutica 2015 Dubai 16th April 2015 Monitoring and inhibiting phase separation of amorphous solid dispersions Dr Min Zhao Min.zhao@ucl.ac.uk Department of Pharmaceutics UCL School of Pharmacy, UK 1

  2. Content • Rationale of amorphous solid dispersion used for poorly water soluble drugs • Stability issues with amorphous solid dispersions • Analytical tools for monitoring phase separation • A promising approach to inhibiting moisture induced phase separation 2

  3. Poorly water soluble drugs • More than 40% of newly discovered drugs have very low water solubility; • 90% of drugs approved since 1995 have bioavailability issues. Source: Connors, R.D. and Elder, E.J. Solubilization Solutions, www.drugdeliverytech.com • For most pharmaceutical companies many drugs in the pipeline fall into Class II of the Biopharmaceutical Classification Systems (BCS). 3

  4. Depending on the properties of the poorly soluble drugs different formulation strategiesare applied Chemical modification: • Pro drugs • Salt formation Alteration of solvent system: • pH adjustment • Co-solvent Carrier systems: • Solid Dispersions • Complexation; • Liposomes • Emulsions • Cocrystals Physical modification: • Micronization • Nanosizing • Polymorph • Changing crystal habit 4

  5. Why amorphous solid dispersions? • Decrease in crystallinity – amorhous material has high solubility due to disordered structure • Reduction of drug particle size to molecular level (increased surface area of the drug) • Reduced or absence of aggregation and agglomeration due to the presence of polymer • Improved wettability due to intiminate contact with hydrophilic polymers 5

  6. Processing methods Melting/fusion---HME Solvent --- Spray Drying 老年痴呆治疗药 Reference: Zhao et al. (2012) Eur. J. Pharm. Biopharm Hot Melt Extruder 6

  7. Content • Rationale of amorphous solid dispersion used for poorly water soluble drugs • Stability issues with amorphous solid dispersions • Analytical tools for monitoring phase separation • A promising approach to inhibiting moisture induced phase separation 7

  8. Stability issues – amorphous solid dispersions • Will recrystallise - amorphous materials undergo nucleation and growth • Will relax – amorphous materials are very dynamic and will undergo relaxation towards equilibrium state • Tendency to absorb water All may cause phase separation!!! 8

  9. Content • Rationale of amorphous solid dispersion used for poorly water soluble drugs • Stability issues with amorphous solid dispersions • Analytical tools for monitoring phase separation • A promising approach to inhibiting moisture induced phase separation 9

  10. 1) Acquiring the imaging -- Atomic Force Microscopy (AFM) • Laser onto probe • Reflection to photodetector • Probe engaged on surface • Closed feedback loop • Probe deflection held at constant deflection • Sample or probe adjusted • Topographic/deflection information 10

  11. Identifying phase separation of HME systems using AFM Phase 2 Phase 1 Corresponding AFM topography images HPMC AS LF/API (70/30) strand granule Extrudate studied by SEM How to determine what the phases are??? – Local Thermal Analysis (LTA) 11

  12. DerivativeMicro-MDTA Micro-TMA Sample Temperature DerivativeMicro-MDTA Micro-TMA Sample Temperature Sample DerivativeMicro-MDTA Micro-TMA Temperature 2) Heating the tip --- Localised Thermal Analysis (LTA) • Image acquired with AFM • Location selected on surface • Probe being heated with voltage profile applied • Onset of phase transition detected as probe penetration 12

  13. Better understanding separated phases using LTA x x x x x x x 13

  14. 3) Mapping --- Transition Temperature Microscopy (TTM) 14

  15. Phase distribution studied by TTM Crystal drug Drug/Polymer dispersions (Majority in Green: 90-110C) API has a Tm at circa 150 ºC and Tg at 44.6 ºC; Polymer has a Tg at 120-125 ºC 15

  16. Content • Rationale of amorphous solid dispersion used for poorly water soluble drugs • Stability issues with amorphous solid dispersions • Analytical tools for monitoring phase separation • A promising approach to inhibiting moisture induced phase separation 16

  17. Aim of the study • Aim: to investigate the stabilizing effect of “zein” on preventing moisture induced phase separation of amorphous dispersions prepared by spray drying. • Zein: • major storage protein of corn • with a wide application in food industry and more recently in the pharmaceutical arena • a versatile excipient due to its low toxicity, sustainable production source and biodegradable nature • has been used to form hydrophobic coatings 17

  18. Methods Preparation: Fully amorphous BUT sensitive to water!!! • Binary system: Paracetamol + Plasdone.1% w/v total solids (30:70 w/w drug/polymer). Solvent: distilled water. • Ternary system: Paracetamol + Plasdone + Zein. 1% w/v total solids (30:70:10 w/w drug/polymer/zein). Solvent 50:50 distilled water/ethanol. Storage condistion: • 25ºC/53%RH over 3 months Characterization: • MTDSC (Modulated Temperature Differential Scanning Calorimetry) • TGA (Thermogravimetric Analysis) • DVS (Dynamic Vapour Sorption) coupled with Microscope 18

  19. DVS results Binary Ternary 19

  20. DVS microscope images over %RH scanning 20

  21. TGA results over 3 months 21

  22. MTDSC results after 3 weeks Binary system Ternary system 22

  23. Conclusions: • Characterisation of physical structure of amorphous solid dispersions, especially phase separation may require novel techniques such as AFM based LTA and TTM. • Zein may be a potential stabilizer for inhibiting moisture induced phase separation. 23

  24. Acknowledgements: Dr Jonathan Moffat --- Oxford Instrument Celia Orive Surface Measurement Systems, UK Shire Pharmaceuticals UK 24

More Related